Clinical trial
Dapagliflozin DPPIV Inhibitor add-on Study
NCT00984867
Study timeline
Study start (unknown)2009-10-01Date precision: month
Registry last updated2014-06-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetesunresolved
Interventions
DapagliflozinDRUG · verified · RxNorm: dapagliflozin
PlaceboDRUG
Sponsors & collaborators
AstraZenecalead sponsor
Bristol-Myers Squibbcollaborator
Mapped research locations
Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1MiamiFlorida, United States1San AntonioTexas, United States1CincinnatiOhio, United States1ColumbusOhio, United States1BerlinGermany1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1Salt Lake CityUtah, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00984867 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.